潜在生物标志物：在过继性细胞治疗中鉴定强大的肿瘤特异性 T 细胞。
Potential biomarkers: Identifying powerful tumor specific T cells in adoptive cellular therapy.
机构信息
Cell Transplantation and Gene Therapy Institute, The Third Xiangya Hospital, Central South University, Changsha, China.
Department of Radiology, The Third Xiangya Hospital of Central South University, Changsha, China.
出版信息
Front Immunol. 2022 Nov 14;13:1003626. doi: 10.3389/fimmu.2022.1003626. eCollection 2022.
Tumor-specific T cells (TSTs) are essential components for the success of personalized tumor-infiltrating lymphocyte (TIL)-based adoptive cellular therapy (ACT). Therefore, the selection of a common biomarker for screening TSTs in different tumor types, followed by expansion to clinical number levels can generate the greatest therapeutic effect. However, studies on shared biomarkers for TSTs have not been realized yet. The present review summarizes the similarities and differences of a number of biomarkers for TSTs in several tumor types studied in the last 5 years, and the advantages of combining biomarkers. In addition, the review discusses the possible shortcomings of current biomarkers and highlights strategies to identify TSTs accurately using intercellular interactions. Finally, the development of TSTs in personalized TIL-based ACT for broader clinical applications is explored.
肿瘤特异性 T 细胞（TSTs）是个性化肿瘤浸润淋巴细胞（TIL）过继细胞治疗（ACT）成功的关键组成部分。因此，选择一种通用的生物标志物来筛选不同肿瘤类型的 TSTs，然后进行扩增至临床数量水平，可以产生最大的治疗效果。然而，目前尚未实现用于 TSTs 的共享生物标志物的研究。本综述总结了过去 5 年来研究的几种肿瘤类型中用于 TSTs 的多个生物标志物的相似点和不同点，以及联合使用生物标志物的优势。此外，还讨论了当前生物标志物可能存在的缺点，并强调了使用细胞间相互作用来准确识别 TSTs 的策略。最后，探讨了 TSTs 在个性化 TIL 为基础的 ACT 中的发展，以实现更广泛的临床应用。
Zotero 插件